top of page

SCIENTIFIC PROGRAMME

Thursday, March 21, 2024

 

08.30                 Registration Opens

09.30 - 09.40   Welcome Address

Michael von Bergwelt, Munich, Germany

09.40 - 11.10   Plenary Session 1: Basic Tumor Immunology

Chair: Sebastian Kobold, Munich, Germany & Niroshana Anandasabapathy, New York, NY, USA

 

09.40 - 10.10   
01.01. Tissue resident macrophages and cancer

Julie Helft, Paris, France

 

10.10 - 10.40   
01.02. Nociception and cancer immunosurveillance

Sebastien Talbot, Kingston, ON, Canada

 

10.40 - 11.10   
01.03. Understanding T cell metabolism to improve cancer immunotherapy

Mathias Wenes, Geneva, Switzerland

11.10 - 11.40   Coffee Break

11.40 - 13.10   Plenary Session 2: New Targets and New Leads

Chair: Jose Saro, Plan-Les-Ouates, Switzerland & Pedro Romero, Lausanne, Switzerland

11.40 - 12.10   
02.01. Type I IFN , DC and anti-tumor immunity

Stefani Spranger, Boston, MA, USA

 

12.10 - 12.40   
02.02. Immunocytokines

Dario Neri, Zurich, Switzerland

 

12.40 - 13.10   
02.03. Targeting TBK1 to overcome resistance to immunotherapy

Russel W. Jenkins, Boston, MA, USA

13.10 - 13.40   Satellite Symposium

Click HERE to read more

13.40 - 15.00   Lunch & Poster Viewing

15.00 - 17.00   Plenary Session 3: Exploiting B Cells and Other Cell Types

Chair: Andrea Schmidts, Munich, Germany & Mascha Binder, Basel, Switzerland

15.00 - 15.30   
03.01. iPSC-derived strategies for cancer immunotherapy

Maria Themeli, Amsterdam, The Netherlands
 

15.30 - 16.00   

03.02. Myeloid ontogeny and metabolic rewiring in the tumor microenvironment

Serena Vegna, Amsterdam, The Netherlands

 

16.00 – 16.15            

03.03. Tertiary lymphoid structures in pancreatic cancer resemble lymphoid follicles in secondary lymphoid organs as sites for

initiation and maintenance of anti-tumor T- and B-cell responses

Kerstin Wennhold, Cologne, Germany

 

16.15 – 16.30            

03.04. Targeted disruption of tumor-borne GDF-15-mediated immunoresistance restores immune checkpoint inhibitor activity in last-line cancer patients

Christine Schuberth-Wagner, Planegg-Martinsried, Germany

 

16.30 – 16.45            

03.05. DSP216 blocks HLA-G and CD47 signaling toward immune cells and restores anti-cancer activity

Lisa Jacob, Groningen, The Netherlands

 

16.45 – 17.00            

03.06. Cancer-specific oral microbiotherapy for cancer immunotherapy

Chong-xian Pan, Boston, MA, USA

17.00 - 18.00   Plenary Session 4: ITOC10 Keynote Lecture

Chair: Christoph Zielinski, Vienna, Austria

04.01. The role of the Homo sapiens in the emergence and the management of the climate crisis

Dr. Philipp Blom, Vienna, Austria

18.00 - 20.00    Networking Event and Poster Viewing (at the venue)

Friday, March 22, 2024

08.15 – 08.30   Late breaking abstract: Controversies in Immuno-Oncology

Chair: Michael von Bergwelt, Munich, Germany & Sebastian Kobold, Munich, Germany

08.15 – 08.30

LB 01.01. Targeting IL-2 activated lymphocytes against otherwise incurable multi-drug resistant hematologic malignancies

potentially competing with CAR-T cells

Shimon Slavin, Tel Aviv, Israel

08.30 – 09.30   Plenary Session 5: Microbiome

Chair: Hendrik Poeck, Regensburg, Germany & Caroline Alves Costa Silva, Villejuif, France

08.30 – 09.00   
05.01. Microbiota modulation of cancer immunotherapy

Caroline Alves Costa Silva, Villejuif, France

 

09.00 – 09.30
05.02. Impact of microbiome on CAR T cell efficacy

Christoph Stein-Thöringer, Tübingen,  Germany

09.30 – 10.30   Plenary Session 6: Pro & Contra Sessions: Adjuvant vs Neoadjuvant IO Treatment

Chair: Christoph Zielinski, Vienna, Austria & Lucie Heinzerling, Munich, Germany

09.30 – 10.00   
06.01. Pro-Adjuvant
 

Alexander Eggermont, Utrecht, The Netherlands

 

10.00 – 10.30   
06.02. Pro-Neoadjuvant

Christian Blank, Leiden, The Netherlands

10.30 – 11.00   Coffee Break

11.10 – 12.30    Plenary Session 7: Combination Therapies

Chair: Chong-Xia Pan, Boston, MA, USA & Tanja De Gruijl, Amsterdam, The Netherlands

11.00 – 11.30   
07.01. Intradermal CpG/tilsotolimod treatment in pT3-4 cN0M0 melanoma: efficacy update of the randomized 
INTRIM trial

Tanja de Gruijl, Amsterdam, The Netherlands

 

11.30 – 12.00   
07.02. Tuning bispecific antibody application and rationale combinations for optimal therapies

Marion Subklewe, Munich, Germany

 

12.00 – 12.30   

07.03. The role of TLS in the response to IO agents

Antoine Italiano, Bordeaux, France

12.30 – 14.30   Lunch & Poster Viewing

14.30 – 15.15   Plenary Session 8: ITOC10 Lifetime Achievement Award presented to Prof. Dr. Andrea Schietinger

Chair: Sebastian Kobold, Munich, Germany & Michael von Bergwelt, Munich, Germany

08.01. Deciphering mechanisms of T cell exhaustion

Andrea Schietinger, New York, NY, USA

15.15 - 16.30   Plenary Session 9: Immuno-Monitoring

Chair: Michael Bergmann, Vienna, Austria & Eric Tartour, Paris, France

15.15 – 15.45   
09.01. Multidimensional dissection of tumor-immune interaction

Rebekka Schneider-Kramann, Aachen, Germany

 

15.45 - 16.15   
09.02. CODEXing the TME
Christian Schürch, Tübingen, Germany

 

16.15 - 16.30   

09.03. Characterization of T cell specificity and exercise-induced dynamics of soluble immunological markers before and after high-intensity aerobic exercise (INHALE)

Katharina Leuchte, Herlev, Denmark

16.30 - 17.00   Coffee Break
 

17.00 - 18.00   Plenary Session 10: Young Researcher Session (from submitted abstracts)

Chair: Louisa von Baumgarten, Munich, Germany & Stefan Endres, Munich, Germany

17.00 – 17.15            

10.01. Prostanoid-insensitive chimeric antigen receptor modified T cells mediate therapeutic efficacy in solid cancer models

Janina Dörr, Munich, Germany

 

17.15 – 17.30            

10.02. Combined anti-angiogenic treatment to increase intratumoral persistence of CAR T-cells in lung cancer brain metastases

Constantin Eberle, Munich, Germany

 

17.30 – 17.45            

10.03. Long lasting alterations of the immunophenotype and cytokine signature of DLBCL survivors results in persisting immune dysfunction

Giulia Benintende, Erlangen, Germany

 

17.45 – 18.00            

10.04. Spatial transcriptomics identifies metabolic dysregulation as a key driver of T cell exclusion in esophageal adenocarcinoma

Jasper Sanders, Amsterdam, The Netherlands

18.00 - 19.00   Poster Viewing with Presenters

20.00                ITOC10 Conference Dinner


Saturday, March 23, 2024

08.00 – 09.00    Plenary Session 11: Reaching New Grounds in Cellular Therapies

Chair: Michael von Bergwelt, Munich, Germany & Fabian Müller, Erlangen, Germany

08.00 – 08.30   
11.01. CD19 CAR T in B cell driven auto-immune disease

Fabian Müller, Erlangen, Germany

 

08.30 – 09.00   

11.02. TIL have come back of age in Melanoma

Troels Holz Borch, Herlev, Denmark

09.00 – 10.30    Plenary Session 12: Cell therapies in Hematologic Oncology

Chair: Marion Subklewe, Munich, Germany & Ulrich Jäger, Vienna, Austria

09.00 – 09.30   
12.01. Leveraging metabolites to boost CAR T cell activity in hematology

Hendrik Poeck, Regensburg, Germany

 

09.30 – 10.00   
12.02. Cellular immunotherapy beyond CAR T cells in hematology

Jianzhu Chen, Cambridge, MA, USA

 

10.00 – 10.30   
12.03. New approaches for cellular therapies in AML

Saar Gill, Philadelphia, PA, USA

10.30 – 11.00    Coffee Break

11.00 – 12.30    Plenary Session 13: Cell Therapies in Solid Oncology

Chair: Mike Luu, Würzburg, Germany & Johanna Olweus, Oslo, Norway

11.00 – 11.30   
13.01. CAR-T in prostate cancer

Vivek Narayan, Philadelphia, PA, USA

                           

11.30 – 12.00   

13.02. Engineering cytokine functionalities in CAR T cells

Saul Priceman, Duarte, CA, USA

 

12.00 – 12.15            

13.03. Empowering TCR-T cells for adoptive therapy for solid tumor through engineering with PD-1-based chimeric 

costimulatory switch proteins

Elfriede Noessner, Munich, Germany

 

12.15 – 12.30            

13.04. Improving the efficacy of TCRtg T cell therapy for solid tumors with mRNA-based vaccination

Janna Krueger, Tübingen, Germany

 

12.30 – 12.45            

13.05. A Novel Approach for Neoantigen Discovery from Splicing Factor Mutated Cancers

Teryn Mitchell, New York, NY, USA

12.45 – 13.15    Plenary Session 14: Best Poster Awards & Closing Remarks

Chair: Tanja De Gruijl, Amsterdam, The Netherlands & TBA

13.15 – 14.15    Lunch & Farewell

bottom of page